EYPT EyePoint Corp Total Debt to Capital

Despite the risks of raw material logistics disruptions due to geopolitics, EyePoint Pharmaceuticals (EYPT) dominates the niche of micro-implants for prolonged ocular treatment. The financial leverage ratio (total debt-to-equity) on GURU.Markets places the current level at approximately 0.12, stripping the debt dynamics of noise. This is critical amid growing demand from clinics to reduce injection frequency for macular degeneration.

EYPT: EyePoint Pharmaceuticals, Inc. Total Debt to Capital 07/04/2022 - 10/28/2026

Analytical breakdowns and data insights for company EyePoint Corp (EYPT)

- price and consensus price forecast:

Price Chart EyePoint Pharmaceuticals, Inc.|EYPT - Forecast Levels Chart

- market capitalization data:

Market Capitalization EyePoint Pharmaceuticals|EYPT - Value Adjusted for Debt and Cash

- book capitalization data:

Book Value per Share EyePoint Pharmaceuticals|EYPT - Book Capitalization|Market Value to Book Value Ratio eyepointpharma.com|EYPT - Aggregate Asset Value

- debt and liquidity data:

Debt to Equity EyePoint Pharmaceuticals|EYPT - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital EyePoint Pharmaceuticals|EYPT - Company Aggregate Debts|Debt to Book Value EyePoint Pharmaceuticals|EYPT - Company Long-Term Loans and Borrowings|Company Short-Term Debts EyePoint Pharmaceuticals

Comprehensive company analysis:EYPT - EyePoint Pharmaceuticals, Inc.

Selecting stocks with a high margin of fundamental strength begins with an analysis of the debt load. This metric compares total liabilities to equity, determining the business's degree of dependence on borrowed funds. For EyePoint Pharmaceuticals (EYPT), low leverage is critical to maintaining exceptional pricing power over its proprietary implants. Increasing indebtedness could create a risk of a liquidity gap. This trend on GURU.Markets is reflected by the total debt-to-equity ratio.

Main competitors